A5063084653- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Brain Metastases and Treatment
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Cancer survivorship and care
- Cancer-related cognitive impairment studies
- Health Systems, Economic Evaluations, Quality of Life
- Nanoplatforms for cancer theranostics
- Immunotherapy and Immune Responses
- Synthesis of Tetrazole Derivatives
- Glioma Diagnosis and Treatment
- Computational Drug Discovery Methods
Copenhagen University Hospital
2022-2025
Gentofte Hospital
2021-2024
BackgroundClinical trials have demonstrated promising outcomes for adjuvant immunotherapy in patients with resected melanoma. Real-life data provide valuable insights to support patient guidance and treatment decisions.MethodsObservational population-based study examining a national cohort of stage III-IV melanoma referred therapy. Data were extracted from the Danish Metastatic Melanoma Database (DAMMED).ResultsBetween November 2018 January 2022, 785 received anti-PD-1. The majority had III...
Treatment with immune checkpoint inhibitors (ICI) has expanded into the adjuvant setting enhancing importance of knowledge on immune-related toxicities and their impact health-related quality life (HRQoL). Large phase 3 trials patients resected Stage III/IV melanoma found no effect HRQoL during immunotherapy. This study investigates how was affected after immunotherapy in a real-world setting.Patients treated nivolumab from 2018 to 2021 Denmark were identified using Danish Metastatic...
The introduction of modern therapies improved the median survival patients with metastatic melanoma (MM). Here, we determined real-world impact treatments on long-term MM.In a population-based study, extracted all cases MM diagnosed in four non-consecutive years marked by major changes available 1st line (2012, 2014, 2016, and 2018) from Danish Database. Patients were grouped into "trial-like" "trial-excluded" based common trial eligibility criteria.We observed sustained 2016 or 2018,...
Novel medical therapies have revolutionized outcome for patients with melanoma. However, melanoma brain metastases (MBM) still poor survival. Data are limited as these generally excluded from clinical trials, wherefore real-world data on may support evidence-based treatment choices MBM. Patients diagnosed MBM between 2008 and 2020 were included retrospectively. Patient characteristics, treatment, recorded The Danish Metastatic Melanoma Database, pathology registries, electronic patient...
Modern therapies targeting the BRAF gene mutation in advanced melanoma have significantly improved patient outcomes but pose cardiovascular risks. This retrospective study Eastern Denmark (2019–2022) assessed 108 patients treated with encorafenib and binimetinib. Patients were monitored for heart function using multigated acquisition (MUGA) scans. The defined major cardiotoxicity as a decline left ventricular ejection fraction (LVEF) by more than 10 percentage points to below 50%, minor...
Combination therapy with BRAF and MEK inhibitors (BRAF/MEKi) has significantly improved the outcome for patients BRAF-mutated melanoma. A reduction in left ventricular ejection fraction (LVEF) is a known side effect during treatment BRAF/MEKi. This study aimed to analyze sequential multigated acquisition (MUGA) scans evaluation of LVEF provide real-world data on cardiotoxicity induced by BRAF/MEKi advanced melanoma.All melanoma treated dabrafenib trametinib at Herlev Gentofte Hospital,...